symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CYDY,0.16765,0.162806,1481089,156075444,0,0.15-0.48,-0.0038,CytoDyn Inc.,USD,0001175680,US23283M1018,23283M101,Other OTC,PNK,Biotechnology,https://www.cytodyn.com,"CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Mr. Antonio  Migliarese CPA,Healthcare,US,12,360 980 8524,1111 Main Street,Vancouver,WA,98660,0.0577664,1.19777,https://financialmodelingprep.com/image-stock/CYDY.png,2006-12-13,False,False,True,False,False
